Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Bimosiamose 5% Cream for the Treatment of Patients With Chronic Plaque Type Psoriasis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00823693

Enrollment

107

Registered

2009-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2009-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Brief summary

The purpose of this study is to determine whether Bimosiamose Cream is safe and effective in the treatment of plaque type psoriasis.

Interventions

DRUGBimosiamose Cream

DRUGPlacebo Cream

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of plaque type psoriasis PASI score of 5-15 * At least 18 years of age * Written informed consent

Exclusion criteria

* Active skin infection * More than 20% Body Surface Area (BSA) affected by psoriasis * Use of certain anti-psoriasis medication or treatments

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026